Ohio Valley Node
The Ohio Valley Node (OVN) joined the Clinical Trials Network in September 2000. The OVN includes successful partnerships with six healthcare systems, two pharmacy networks, and six addiction specialty/ infectious disease programs. These collaborating
sites span a seven-state region including some of the states most heavily impacted by opioid (Ohio, Kentucky, and West Virginia) and methamphetamine (Missouri, Kentucky, and North Dakota) use. The OVN includes Midwestern, Appalachian, Upper South,
and Native American representation, which significantly enhances the geographical and cultural diversity of the CTN. The OVN has an outstanding history of successful participation in CTN clinical trials: 17 OVN sites, located in seven different states,
have served in >30 CTN trials. Completed trials are listed below.
See completed list of Projects
| CTN-0001 | Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification |
| CTN-0002 | Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification |
| CTN-0008 | Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation |
| CTN-0012 | Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs |
| CTN-0013 | Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome in Pregnant Substance Users |
| CTN-0014 | Brief Strategic Family Therapy for Adolescent Drug Abusers |
| CTN-0014-A-1 | Mediators and Moderators of Brief Strategic Family Therapy (BSFT) for Adolescent Drug Use |
| CTN-0015 | Women's Treatment for Trauma and Substance Use Disorders |
| CTN-0018 | Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment |
| CTN-0019 | Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment |
| CTN-0028 | Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents (with Substance Use Disorder) |
| CTN-0029 | Attention Deficit Hyperactivity Disorder (ADHD) in Adult Smokers |
| CTN-0030 | Prescription Opioid Addiction Treatment Study (POATS) |
| CTN-0030-A-1 | Collection of Economic Data for the Prescription Opioid Addiction Treatment Study |
| CTN-0031 | Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement |
| CTN-0031-A-1 | An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers |
| CTN-0032 | HIV Rapid Testing and Counseling |
| CTN-0032-A-1 | Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs |
| CTN-0033-Ot-4 | An Exploration of Methamphetamine and Other Drug Use and Treatment Options Among Urban and Rural Northern Plains American Indians |
| CTN-0037 | Stimulant Reduction Intervention Using Dosed Exercise (STRIDE) |
| CTN-0037-A-1 | Site Influences on Treatment Effects - Exercise as a Treatment for Substance Use Disorders |
| CTN-0042-S | Efficacy of Motivational Enhancement Therapy for African Americans |
| CTN-0044 | Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders |
| CTN-0044-A-2 | Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native |
| CTN-0046 | Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence |
| CTN-0047 | Screening Motivational Assessment and Referral to Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department |
| CTN-0048 | Cocaine Use Reduction with Buprenorphine (CURB) |
| CTN-0049 | Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users (Project HOPE) |
| CTN-0051 | Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) |
| CTN-0051-A-1 | Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study |
| CTN-0051-A-2 | Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051 |
| CTN-0052 | Buspirone for Relapse Prevention in Adults with Cocaine Dependence (BRAC) |
| CTN-0053 | Achieving Cannabis Cessation -- Evaluating N-Acetylcystein Treatment (ACCENT) |
| CTN-0055 | Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES) |
| CTN-0064 | Linkage to Hepatitis C Virus (HCV) Care among HIV/HCV Co-infected Substance Users |
| CTN-0067 | Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES); Scale-Up |
| CTN-0069 | Opioid Use Disorder in the Emergency Department |
| CTN-0093 | Validation of a Community Pharmacy-based Prescription Drug Monitoring Program Risk Screening Tool (PHARMSCREEN) (NIH HEAL Initiative) |